Last edition
News about "Antengene"
Antengene Licenses ATG-106 to K2 Therapeutics in Strategic Deal
Antengene has granted K2 Therapeutics exclusive global rights to develop and commercialise ATG-106 outside Greater China under a strategic licensing agreement that also includes an option for an undisclosed bispecific T-Cell Engager (TCE).
Antengene | 24/06/2026 | By News Bureau | 122
Antengene Corporation receives CDE endorsement to begin pivotal phase 3 CLINCH-3 study of ATG-022
Antengene has received approval from China’s Center for Drug Evaluation to initiate the pivotal Phase 3 CLINCH-3 study of ATG-022, advancing the development of its innovative antibody-drug conjugate for CLDN18.2-positive gastric cancers.
Antengene | 30/05/2026 | By News Bureau
Antengene Receives Approval for XPOVIO for Commercialisation in Thailand
This successful approval for XPOVIO in Thailand will introduce novel therapies to the clinical management of patients with MM in Thailand, benefiting many patients and their families in the country.
Antengene | 24/09/2024 | By Aishwarya | 735
Antengene Gets Malaysian Regulatory Agency Approval for XPOVIO Commercialization
Antengene has announced that Malaysian National Pharmaceutical Regulatory Agency has approved a New Drug Application (NDA) for XPOVIO (selinexor).
Antengene | 06/08/2024 | By Aishwarya | 689
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy